Oyster Point Pharma, Inc.

Oyster Point Pharma, Inc. (OYST) priced its initial public offering on Oct 31, 2019 at $16.00 per share, within its $16.00–$18.00 range, raising $80M, and listed on Nasdaq Global Select. At the IPO price its market capitalization was about $329.8M. Wilson Sonsini advised the company and Latham & Watkins advised the underwriters.

Oyster Point Pharma, Inc. is a clinical-stage biopharmaceutical company developing therapies for ocular surface diseases. Its lead candidate, OC-01 (varenicline), is a nasal spray for the signs and symptoms of dry eye disease and showed significant improvements over placebo in a Phase 2b trial of 182 subjects.

Status

IPO

Ticker

OYST

Exchange

Nasdaq Global Select

Priced

Oct 31, 2019

IPO price

$16.00

Price range

$16.00–$18.00

Raised

$80M

Market cap at IPO price

$329.8M

First filed

Oct 4, 2019

Company counsel

Wilson Sonsini

Underwriters' counsel

Latham & Watkins

Sector

Biotech & pharma

Country / state

NJ

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.